Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

LLMC 2020 | The future of CLL treatment: more selective and reversible BTK inhibitors

Jennifer Woyach • 21 Oct 2020

LLMC 2020

Chronic Lymphocytic Leukemia Acalabrutinib ARQ 531 Pirtobrutinib

Jenifer Woyach, MD, The Ohio State University, Columbus, OH, discusses the future directions of research into treatments for chronic lymphocytic leukemia (CLL). Dr Woyach highlights ongoing research on acalabrutinib which may offer safety benefits over existing standard of care regimens (NCT04008706) and treatment options for patients who have progressed following BTK inhibitor treatment using reversible BTK inhibitors, including Phase I/II trials of LOXO-305 (NCT03740529) and ARQ 531 (NCT03162536). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Disclosures

Consulting/advisory boards: Janssen, Pharmacyclics, Abbvie, AstraZeneca, Arqule

6-year follow-up of ELEVATE-TN: sustained safety and efficacy in CLL

Jennifer Woyach • 8 Dec 2023

Pirtobrutinib in patients with CLL/SLL previously exposed to covalent BTKi: insights from BRUIN

Jennifer Woyach • 8 Dec 2023

LP-168: a novel next-generation BTK inhibitor with dual activity in CLL

Jennifer Woyach • 8 Dec 2023

BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLL

Jennifer Woyach • 7 Oct 2023

Related Videos

EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation

Valentin Ortiz-Maldonado • 16 Apr 2024

A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies

Pau Abrisqueta • 5 Apr 2024

Early detection and interception across hematological cancers

Irene Ghobrial • 8 Apr 2024

Monoclonal B-cell lymphocytosis: a disease to be (or not to be)

Paolo Ghia • 7 Apr 2024